摘要
目的探讨肝动脉栓塞化疗(TACE)联合经皮射频消融(RFA)在治疗结肠癌肝转移的优势和实用价值。方法选择近年来收治的结直肠癌肝转移50例患者,分为全身化疗组(20例)和TACE+RFA组(30例)。应用流式细胞仪检测患者治疗前后外周血CD3+、CD4+、CD8+、CD19+、CD16+CD56+和CD4+/CD8+的变化,评价其对免疫功能的影响;同时复查患者治疗3月后AFP的情况。并且根据临床治疗情况分析其生存率。结果 TACE+RFA组治疗后免疫功能评价(CD3+、CD4+、CD16+CD56+和CD4+/CD8+)较治疗前有显著性差异(P<0.05),全身化疗组治疗后较治疗前无统计学意义(P>0.05);TACE+RFA组治疗后AFP含量为(34.37±1.35ng/mL),与全身化疗组(29.21±3.82)相比无统计学差异,并且平均生存时间也较全身化疗组显著延长(P<0.05)。结论动脉栓塞化疗联合经皮射频消融可明显改善患者免疫功能,提高临床疗效,延长生存期。
Objective to investigate the advantages and practical value of transcatheter hepatic arterial chcmoembolization （TACE） combined with radiofrequency ablation （RFA） for treating hepatic metastasis of colon carcinoma. Methods 50 patients with hepatic metastasis of colon carcinoma were divided into the whole body chemotherapy group （WBCG） （20 cases） and TACE ＋ RFA group （TRG） （30 cases）. Flow cytometry was used to mea- sure the changes of CD3＋ .CD4＋ .CD8＋、CD19＋、CD16＋、CD56＋ 、和 CD4＋/CD8＋ in peripheral blood before and after the operation, assessed its ef- fect to immune function; AFP was checked after three months treatment with analyzing the survival rate according to clinical treatment. Results In TACE ＋ RFA group, the values of CD3＋、CD4＋、CD16＋ CD56＋ 和 CD4＋/CD8＋ were significant lower than after operation （P〈 0.05）. The other group is no different statistical meaning （ P 〉 0.05） ; AFP is 34.37±1.35ng/mL in TACE ＋ RFA with no statistical difference compared to the other group （29.21±3.82） ; the average survival time is obviously longer than the other group（ P 〈 0.05）. Conclusions Immune function of patients is obvi- ously improved by TACE and RFA which can enhance clinical treatment and prolong the survival time.
出处
《中国病案》
2012年第7期69-70,共2页
Chinese Medical Record
关键词
肝动脉栓塞化疗
射频消融
结肠癌
肝转移
Transcatheter hepatic arterial ehemoembolization
Rediofrequency ablation
Colon carcinoma
Hepatic metastasis
